



BP Reference Standards



Medicines & Healthcare products
Regulatory Agency

Overview of newly released CRS to support BP 2027 monographs

CODE NO.	NAME	BATCH NUMBER	PACK SIZE	INTENDED PURPOSE
BP-1336	Indapamide impurity Standard	4921	25 mg	Peak identity standard
BP-1324	Carbidopa impurity standard	4897	25 mg	Peak identity standard
BP-1325	Carbidopa Impurity 1	4898	25 mg	Peak identity standard
BP-1326	Tyrosine (Levodopa impurity B)	4899	25 mg	Peak identity standard
BP-1327	3-Methoxytyrosine (Levodopa impurity C)	4900	10 mg	Peak identity standard
BP-1331	Timolol impurity standard	4950	25 mg	Peak identity standard
BP-1322	Topiramate	4894	100 mg	Peak identity standard
BP-1323	Topiramate impurity A	4896	25 mg	Peak identity standard
BP-1329	Ropinirole impurity A	4902	25 mg	Peak identity standard
BP-1330	Ropinirole for peak identification	4903	10 mg	Peak identity standard
BP-1333	Melatonin impurity 1	4912	15 mg	Peak identity standard
BP-1334	Clobetasol impurity C	4913	15 mg	Peak identity standard

BP Reference Standards



Medicines & Healthcare products
Regulatory Agency

More information on the newly released standards

Carbidopa impurity standard. (for peak identification)

Carbidopa Impurity 1. (for peak identification)

Tyrosine (Levodopa impurity B). (for peak identification)

3-Methoxytyrosine (Levodopa impurity C). (for peak identification)

The BP 2027 contains new and updated monographs for Co-careldopa Tablets and Co-careldopa Prolonged-release tablets. These contain Carbidopa and Levodopa, which are both listed on the WHO Essential medicine list and used in the treatment of Parkinson's Disease, which affects about 10 million people worldwide.

Ropinirole impurity A. (for peak identification)

Ropinirole for peak identification.

Ropinirole is listed on the WHO Essential medicine list and is used in the treatment of Parkinson's Disease, either alone or in combination with co-beneldopa or co-careldopa. BP 2027 contains new finished product monographs for Ropinirole Tablets and Ropinirole Prolonged-release Tablets.

Topiramate (quantitative assay standard)

Topiramate impurity A (for peak identification).

Topiramate is an anticonvulsant medication which is widely used for the treatment of epilepsy in both children and adults. It is also used for the prevention of migraines. The BP 2027 contains a new monograph for Topiramate Tablets.

Indapamide impurity Standard. (for peak identification)

Indapamide is very widely used in Europe and the UK for the treatment of hypertension (high blood pressure). It is listed on the WHO Essential medicine list for treatment of hypertension and heart failure and its usage is growing rapidly in the Asia-Pacific region. The BPCRS improves peak identification in the updated related substances tests for Indapamide Tablets and Indapamide Prolonged-release Tablets.



BP Reference Standards



Medicines & Healthcare products
Regulatory Agency

More information on the newly released standards

Timolol impurity standard. (for peak identification)

To support an updated Timolol Tablets monograph. Timolol Maleate in oral tablet form is used to treat of angina and hypertension, and for prophylaxis of myocardial infarction and migraine. It is listed on the WHO Essential medicine list.

Melatonin impurity 1. (for peak identification)

Melatonin is used to treat short term insomnia and Jet lag in adults. Melatonin impurity 1 BPCRS supports a number of new and updated Melatonin finished product monographs within BP 2027, including tablets, capsules and oral solution.

Clobetasol impurity C. (for peak identification)

Clobetasol propionate is a potent corticosteroid used in the short-term treatment of previously unresponsive eczema, and psoriasis in children and adults. The BPCRS for impurity C is used in updated product monographs for a family of Clobetasol products including shampoo, scalp application and cutaneous foam.